Treatment Challenges in ALK+ NSCLC (Expired)
Faculty: Charu Aggarwal, MD, MPH and Melina Marmarelis, MD Grant Support: Genentech and Takeda Oncology
Joint Providers: Postgraduate Institute for Medicine and Enquiring Minds, LLC
Access the CME Activity
Tailor treatment plans for 4 patients diagnosed with ALK+ NSCLCL, each of whom may be experiencing comorbid conditions, toxicities, CNS metastases or resistance mutations.
Carol
Carol is a 46-year-old female with minimal smoking history, who presented to her primary care physician with shortness of breath, which she reports has been present for at least 2 months and has been getting progressively worse. A chest CT revealed a left lower lobe mass with mediastinal lymphadenopathy.
Max
Max is a 56-year-old male software engineer with a history of hypertension and hypercholesterolemia. Max presented to his primary care physician 2 years ago with shortness of breath and persistent cough. A PET CT scan confirmed the presence of metastatic disease with evidence of hepatic metastases.
Maria
Maria is a 53-year-old woman who was diagnosed with metastatic NSCLC in 2015. Biopsy of her right upper lobe lung mass revealed adenocarcinoma and molecular testing of her tumor was notable for detection of an EML4-ALK fusion. At a recent follow-up, she has new metastases in the brain without progression in the rest of her disease sites.
Larry
Larry is a 59-year-old male who was recently diagnosed with ALK-positive advanced NSCLC. He was started on first-line systemic therapy 3 weeks ago and has returned for a follow-up toxicity check. Larry reports experiencing 1 to 2 loose stools daily and has 1+ peripheral edema bilaterally. He also reports seeing trailing lights while driving at night.